Michael E. DeBakey VA Medical Center, Houston, Tex; Section of Cardiology, Baylor School of Medicine, Houston, Tex.
Department of Cardiology, University of Toledo, Toledo, Ohio.
Am J Med. 2021 Jul;134(7):e403-e408. doi: 10.1016/j.amjmed.2021.02.011. Epub 2021 Mar 25.
The ideal management of spontaneous coronary artery dissection (SCAD) has yet to be clearly defined. We conducted a comprehensive search of Ovid MEDLINE, Ovid Embase, Ovid Cochrane Database of Systematic Reviews, Scopus, and Web of Science from database inception from 1966 through September 2020 for all original studies (randomized controlled trials and observational studies) that evaluated patients with SCAD. Study groups were defined by allocation to medical therapy (medical therapy) versus invasive therapy (invasive therapy) (ie, percutaneous coronary intervention or coronary artery bypass grafting). The risk of death (risk ratio [RR] = 0.753; 95% confidence interval [CI]: 0.21-2.73; I = 21.1%; P = 0.61), recurrence of SCAD (RR = 1.09; 95% CI: 0.61-1.93; I = 0.0%; P = 0.74), and repeat revascularization (RR = 0.64; 95% CI: 0.21-1.94; I = 57.6%; P = 0.38) were not statistically different between medical therapy and invasive therapy for a follow-up ranging from 4 months to 3 years. In conclusion, in this meta-analysis of observational studies, the long-term risk of death, recurrent SCAD, and repeat revascularization did not significantly differ among patients with SCAD treated with medical therapy compared with those treated with invasive therapy. These findings support the current expert consensus that patients should be treated with medical therapy when clinically stable and no high-risk features are present. Further large-scale studies including randomized controlled trials are needed to confirm these findings.
自发性冠状动脉夹层(SCAD)的理想治疗方法尚未明确界定。我们对 1966 年至 2020 年 9 月期间 Ovid MEDLINE、Ovid Embase、Ovid Cochrane 系统评价数据库、Scopus 和 Web of Science 中的所有原始研究(随机对照试验和观察性研究)进行了全面检索,以评估 SCAD 患者。研究组根据分配到药物治疗(药物治疗)与侵入性治疗(侵入性治疗)(即经皮冠状动脉介入治疗或冠状动脉旁路移植术)进行定义。死亡率(风险比 [RR] = 0.753;95%置信区间 [CI]:0.21-2.73;I = 21.1%;P = 0.61)、SCAD 复发(RR = 1.09;95% CI:0.61-1.93;I = 0.0%;P = 0.74)和重复血运重建(RR = 0.64;95% CI:0.21-1.94;I = 57.6%;P = 0.38)在药物治疗和侵入性治疗之间在 4 个月至 3 年的随访期间没有统计学差异。总之,在这项观察性研究的荟萃分析中,与接受侵入性治疗的患者相比,接受药物治疗的 SCAD 患者的长期死亡率、SCAD 复发和重复血运重建风险没有显著差异。这些发现支持目前的专家共识,即当患者临床稳定且无高危特征时,应采用药物治疗。需要进一步开展包括随机对照试验在内的大规模研究来证实这些发现。